DMRA
Damora Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-11/100
Last price
19.55
▼ 0.67 (3.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
20.22
Day high
20.45
Day low
18.20
Volume
1.17M
Market cap
$1.21B
P/E (TTM)
—
52W range
4.95 – 38.33
Trailing performance
Returnvs SPY
1W
-5.37%
-7.3%
1M
-34.96%
-36.1%
3M
-28.99%
-33.5%
6M
-19.88%
-38.1%
YTD
-15.04%
-29.3%
1Y
+415.83%
+399.4%
3Y
+8.61%
-73.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DMRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+20.08M
Net buying
Buy transactions
39
21.59M shares
Sell transactions
17
1.51M shares
Net transactions
+56
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
5.20M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 25, 26 | JARRETT A JENNIFER Chief Executive Officer |
BUY | 12.50K | $252.88K | Direct |
| Jul 6, 26 | WINSLOW GARRETT General Counsel |
SELL | 245 | $7.34K | Direct |
| Jul 2, 26 | WINSLOW GARRETT General Counsel |
— | 680 | — | Direct |
| Mar 30, 26 | JARRETT A JENNIFER Chief Executive Officer |
— | 500.00K | — | Direct |
| Feb 9, 26 | FAIRMOUNT FUNDS MANAGEMENT LLC Director and Beneficial Owner of more than 10% of a Class of Security |
— | 8.71M | — | Indirect |
| Feb 9, 26 | BRUNO JULIANNE Director |
— | 129.00K | — | Direct |
| Jan 5, 26 | HEWES LEMUEL BECKER Officer |
— | 264.63K | — | Direct |
| Jan 5, 26 | SATTARZADEH SHERWIN Chief Operating Officer |
— | 190.38K | — | Direct |
| Jan 2, 26 | SCHAMBYE HANS T. Chief Executive Officer |
SELL | 700 | $14.97K | Direct |
| Jan 2, 26 | WINSLOW GARRETT General Counsel |
SELL | 255 | $5.45K | Direct |
| Jan 2, 26 | FIRMANI LORI Chief Financial Officer |
SELL | 135 | $2.89K | Direct |
| Jan 2, 26 | SCHAMBYE HANS T. Chief Executive Officer |
— | 1.36K | — | Direct |
| Jan 2, 26 | WINSLOW GARRETT General Counsel |
— | 680 | — | Direct |
| Jan 2, 26 | FIRMANI LORI Chief Financial Officer |
— | 374 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRUNO JULIANNE |
Director | 137.03K | Conversion of Exercise of derivative security |
FAIRMOUNT FUNDS MANAGEMENT LLC |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
FIRMANI LORI |
Chief Financial Officer | 931 | Sale |
HEWES LEMUEL BECKER |
Officer | 264.63K | Stock Award(Grant) |
JARRETT A JENNIFER |
Chief Executive Officer | 512.50K | Purchase |
SATTARZADEH SHERWIN |
Chief Operating Officer | 190.38K | Stock Award(Grant) |
SCHAMBYE HANS T. |
Chief Executive Officer | 4.68K | Sale |
WINSLOW GARRETT |
General Counsel | 2.29K | Sale |
Fundamentals
Market cap$1.21B
Enterprise value$796.41M
Revenue (TTM)—
Gross profit—
EBITDA$-96.33M
Net income$-241.25M
EPS (TTM)$-0.25
Free cash flow$-15.98M
Total cash$540.52M
Total debt$0
Book value / share$6.25
Shares outstanding61.74M
Float40.89M
Short % of float8.95%
Dividend yield0.00%
Beta (5Y)1.44
Valuation & profitability ratios
Trailing P/E—
Forward P/E-9.00
PEG ratio—
Price / sales—
Price / book3.13
EV / revenue—
EV / EBITDA-8.27
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-99.74%
Return on assets-21.61%
Debt / equity—
Current ratio19.73
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $201.19M | $10.79M | $23.77M | $48.21M | +1,764.1% |
| Selling, general & admin | $9.69M | $10.50M | $12.69M | $13.00M | -7.8% |
| Total operating expense | $210.87M | $21.29M | $36.46M | $61.21M | +890.4% |
| Operating income | -$210.87M | -$21.29M | -$36.46M | -$61.21M | -890.4% |
| Net interest income | $1.17M | $844.00K | $1.69M | $722.00K | +38.3% |
| Pre-tax income | -$209.79M | -$21.40M | -$38.35M | -$61.62M | -880.4% |
| Tax provision | $50.00K | $41.00K | $0 | — | +22.0% |
| Net income | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -878.8% |
| Net income to common | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -878.8% |
| Basic EPS | -3.98 | -18.53 | -36.08 | -60.75 | +78.5% |
| Diluted EPS | -3.98 | -18.53 | -36.08 | -60.75 | +78.5% |
| EBIT | -$210.87M | -$21.29M | -$36.46M | -$61.21M | -890.4% |
| EBITDA | -$210.84M | -$21.11M | -$35.63M | -$60.72M | -898.7% |
| Basic shares | 1.36M | 1.16M | 1.06M | 1.02M | +17.8% |
| Diluted shares | 1.36M | 1.16M | 1.06M | 1.02M | +17.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $257.62M | $14.18M | $21.46M | $32.79M | +1,717.5% |
| Cash & short-term investments | $257.62M | $14.18M | $33.15M | $60.22M | +1,717.5% |
| Total current assets | $260.42M | $16.84M | $36.77M | $63.91M | +1,446.5% |
| Property, plant & equipment | $104.00K | $130.00K | $325.00K | $1.17M | -20.0% |
| Total assets | $260.53M | $17.13M | $38.23M | $73.19M | +1,420.7% |
| Total current liabilities | $20.07M | $1.20M | $5.83M | $11.11M | +1,576.4% |
| Total debt | $68.00K | $73.00K | $249.00K | $804.00K | -6.8% |
| Total liabilities | $20.15M | $1.30M | $5.90M | $11.44M | +1,448.6% |
| Retained earnings | -$487.36M | -$277.52M | -$256.08M | -$217.74M | -75.6% |
| Shareholder equity | $240.38M | $15.83M | $32.33M | $61.75M | +1,418.4% |
| Working capital | $240.36M | $15.64M | $30.94M | $52.80M | +1,436.6% |
| Net tangible assets | $240.38M | $15.83M | $32.33M | $61.75M | +1,418.4% |
| Shares issued | 1.60M | 1.32M | 1.08M | 1.03M | +21.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$209.84M | -$21.44M | -$38.35M | -$61.62M | — | -878.8% |
| Depreciation & amortisation | $34.00K | $181.00K | $830.00K | $490.00K | — | -81.2% |
| Stock-based compensation | $998.00K | $3.24M | $5.43M | $5.57M | — | -69.2% |
| Change in working capital | $18.36M | -$2.67M | -$4.37M | $11.94M | — | +788.6% |
| Operating cash flow | -$6.73M | -$18.62M | -$36.91M | -$42.93M | — | +63.9% |
| Capital expenditure | — | — | — | -$196.00K | -$223.00K | — |
| Investing cash flow | -$17.37M | $11.65M | $22.33M | $12.38M | — | -249.1% |
| Financing cash flow | $266.84M | $0 | $2.88M | $507.00K | — | — |
| Free cash flow | -$6.73M | -$18.62M | -$36.91M | -$43.13M | — | +63.9% |
| End cash position | $257.62M | $14.18M | $21.46M | $32.79M | — | +1,717.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $25.54M | $23.78M | $197.63M | $1.42M | $1.47M | — | +7.4% |
| Selling, general & admin | $9.45M | $7.03M | $4.07M | $1.74M | $1.96M | — | +34.4% |
| Total operating expense | $34.99M | $30.81M | $201.70M | $3.16M | $3.42M | — | +13.6% |
| Operating income | -$34.99M | -$30.81M | -$201.70M | -$3.16M | -$3.42M | — | -13.6% |
| Net interest income | $4.06M | $3.07M | $1.00M | $42.00K | $50.00K | — | +32.2% |
| Pre-tax income | -$30.92M | -$27.74M | -$200.69M | -$3.13M | -$3.43M | — | -11.5% |
| Tax provision | $255.00K | $42.00K | $44.00K | $0 | $4.00K | — | +507.1% |
| Net income | -$31.17M | -$27.78M | -$200.74M | -$3.13M | -$3.44M | — | -12.2% |
| Net income to common | -$31.17M | -$27.78M | -$200.74M | -$3.13M | -$3.44M | — | -12.2% |
| Basic EPS | -0.39 | -0.62 | — | -2.36 | -2.60 | -1.92 | +37.1% |
| Diluted EPS | -0.39 | -0.62 | — | -2.36 | -2.60 | -1.92 | +37.1% |
| EBIT | -$34.99M | -$30.81M | -$201.70M | -$3.16M | -$3.42M | — | -13.6% |
| EBITDA | -$34.98M | -$30.74M | -$201.69M | -$3.15M | -$3.41M | — | -13.8% |
| Basic shares | 61.12M | 34.30M | — | 1.33M | 1.32M | 1.32M | +78.2% |
| Diluted shares | 61.12M | 34.30M | — | 1.33M | 1.32M | 1.32M | +78.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $540.51M | $532.90M | $257.62M | $7.61M | $10.21M | — | +1.4% |
| Cash & short-term investments | $540.51M | $532.90M | $257.62M | $7.61M | $10.21M | — | +1.4% |
| Total current assets | $543.59M | $535.41M | $260.42M | $9.79M | $13.03M | — | +1.5% |
| Property, plant & equipment | — | — | $104.00K | $113.00K | $122.00K | $125.00K | — |
| Total assets | $543.64M | $535.44M | $260.53M | $10.74M | $13.69M | — | +1.5% |
| Total current liabilities | $27.55M | $23.81M | $20.07M | $2.62M | $2.63M | — | +15.7% |
| Total debt | — | — | $68.00K | $72.00K | $75.00K | $73.00K | — |
| Total liabilities | $27.58M | $23.84M | $20.15M | $2.73M | $2.74M | — | +15.7% |
| Retained earnings | -$546.32M | -$515.15M | -$487.36M | -$286.63M | -$283.49M | — | -6.1% |
| Shareholder equity | $516.06M | $511.60M | $240.38M | $8.01M | $10.95M | — | +0.9% |
| Working capital | $516.04M | $511.60M | $240.36M | $7.16M | $10.40M | — | +0.9% |
| Net tangible assets | $516.06M | $511.60M | $240.38M | $8.01M | $10.95M | — | +0.9% |
| Shares issued | 61.73M | 60.30M | 1.60M | 1.33M | 1.32M | — | +2.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$31.17M | -$27.78M | -$200.74M | -$3.13M | -$3.44M | — | -12.2% |
| Depreciation & amortisation | $11.00K | $68.00K | $7.00K | $10.00K | $9.00K | — | -83.8% |
| Stock-based compensation | $6.14M | $3.13M | $483.00K | $164.00K | $172.00K | — | +96.0% |
| Change in working capital | $3.15M | $3.98M | $17.14M | $332.00K | $1.02M | — | -20.9% |
| Operating cash flow | -$21.87M | -$20.60M | $566.00K | -$2.62M | -$2.24M | — | -6.2% |
| Investing cash flow | — | — | -$17.37M | $0 | $0 | $0 | — |
| Financing cash flow | $29.50M | $295.92M | — | — | $0 | $0 | -90.0% |
| Free cash flow | -$21.87M | -$20.60M | $566.00K | -$2.62M | -$2.24M | — | -6.2% |
| End cash position | $540.51M | $532.90M | $257.62M | $7.61M | $10.21M | — | +1.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.37 | -0.39 | -5.4% |
| Mar 2026 | -0.65 | — | — |
| Dec 2025 | -0.11 | — | — |
| Sep 2025 | — | -2.36 | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.44 | 4 | $0 | — |
| Next quarter | -0.47 | 4 | $0 | 0.0% |
| Current year | -1.90 | 4 | $0 | 0.0% |
| Next year | -2.17 | 4 | $0 | 0.0% |
Analyst targets & ownership
Mean target$46.89
High target$60.00
Low target$40.00
Implied upside139.84%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy1 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders8.43%
Held by institutions105.78%
Institutions holding151
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
20.47
-4.50% from price
SMA 20
22.71
-13.92% from price
SMA 50
27.02
-27.65% from price
SMA 100
26.30
-25.68% from price
SMA 200
26.04
-24.94% from price
EMA 12
21.25
-8.01% from price
EMA 26
23.41
-16.49% from price
EMA 50
25.21
-22.46% from price
RSI (14)
28.9
Oversold
MACD (12,26,9)
-2.16
Hist -0.06
ATR (14)
1.53
7.82% of price
Realised vol 30D
68.9%
Annualised
Bollinger upper
28.20
20, 2σ
Bollinger lower
17.22
20, 2σ
50 / 200 cross
Golden
27.02 vs 26.04
Trend bias
Below 200
-24.94%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.28
More volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
68.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-72.4%
Peak to trough
Max drawdown 5Y
-97.5%
Peak to trough
ATR 14
1.53
7.82% of price
Beta (reported)
1.44
5Y monthly, from filing
Short interest
Shares short
4.73M
Prior 4.74M
Change vs prior
-0.2%
Shorts covering
% of float
8.95%
Normal
% of shares out
7.67%
Against total outstanding
Days to cover
10.9
Crowded exit
Float
40.89M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 25, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 27, 26 | Jefferies | INITIATED | — | Buy |
| Jul 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 11, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| May 28, 26 | Wedbush | INITIATED | — | Outperform |
| Apr 24, 26 | RBC Capital | INITIATED | — | Outperform |
| Mar 25, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| Feb 17, 26 | UBS | INITIATED | — | Buy |
| Feb 17, 26 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:25
Split dateAug 30, 2024
SEC filings
Offering Registrations
S-8 POS · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-06-17
Periodic Financial Reports
10-Q · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-04
Annual Report to Shareholders
ARS · 2026-05-01
Proxy Statements
DEFA14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-20
Headlines
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing
MT Newswires · 9d ago
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 34d ago
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 58d ago
Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis
MT Newswires · 63d ago
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
GlobeNewswire · 63d ago
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 65d ago
Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating
MT Newswires · 70d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.